Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Drugs and Chemicals›Decorin
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Decorin

Drugs and Chemicals · NLM MeSH · updated 2026-10-31 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 5 min read

A small leucine-rich proteoglycan that interacts with fibrillar collagens and modifies the extracellular matrix structure of connective tissue.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (963 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A small leucine-rich proteoglycan that interacts with fibrillar collagens and modifies the extracellular matrix structure of connective tissue. Decorin has also been shown to play additional roles in the regulation of cellular responses to growth factors. The protein contains a single glycosaminoglycan chain and is similar in structure to biglycan.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: DSPG-II; Bone Proteoglycan II; Proteoglycan II, Bone.

Where it fits in the MeSH classification

Broader topics
Chondroitin Sulfate Proteoglycans; Small Leucine-Rich Proteoglycans

Related concepts

  • Fibrillar Collagens
  • Extracellular Matrix
  • Connective Tissue
  • Growth Factors
  • Biglycan

Research landscape

PubMed indexes 1,846 records tagged with the MeSH heading “Decorin” (counts retrieved 2026-10-31). 292 of them (15.8%) were published from 2020 onward, and the busiest period so far is 2000-2009 with 625 records.

Reviews account for 121 records (6.6%) and meta-analyses for 2. Randomized controlled trials number 13 (0.7%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 389 records; 2000-2009: 625 records; 2010-2019: 540 records; 2020 onward: 292 records389through 19996252000-20095402010-20192922020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 1999389
2000-2009625
2010-2019540
2020 onward292
Share of records by publication typeReviews: 6.6 percent; Meta-analyses: 0.1 percent; Randomized controlled trials: 0.7 percentReviews6.6% (121)Meta-analyses0.1% (2)Randomized controlled trials0.7% (13)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 1,846 PubMed records
TypeRecordsShare
Reviews1216.6%
Meta-analyses20.1%
Randomized controlled trials130.7%

Method: PubMed query "Decorin"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in drugs and chemicals

Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Granzyme B cleaves decorin, biglycan and soluble betaglycan, releasing active transforming growth factor-β1
Boivin WA, Shackleford M, Vanden Hoek A, Zhao H, Hackett TL, Knight DA, et al.
2012Research article
Design not recorded in structured metadata
95cc by
PMID 22479366 · DOI · PMC3316562
Decorin: A Growth Factor Antagonist for Tumor Growth Inhibition
Järvinen TA, Prince S
2015Review article
Design not recorded in structured metadata
94cc by
PMID 26697491 · DOI · PMC4677162
Decorin promotes decidual M1-like macrophage polarization via mitochondrial dysfunction resulting in recurrent pregnancy loss
Wang L, Wang H, Luo J, Xie T, Mor G, Liao A
2022Research article
Design not recorded in structured metadata
85cc by
PMID 36438479 · DOI · PMC9691373
Kisspeptin-10 regulates glycosaminoglycan and decorin content in human cardiac fibroblast cultures
Radwańska P, Olkiewicz M, Piera L, Drobnik J
2026Research article
Design not recorded in structured metadata
0cc by
PMID 42159865 · DOI · PMC13437659

Granzyme B cleaves decorin, biglycan and soluble betaglycan, releasing active transforming growth factor-β1 [1]

Research article Boivin WA, Shackleford M, Vanden Hoek A, Zhao H, Hackett TL, Knight DA, et al. · · 2012 · cited 95 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
ObjectiveGranzyme B (GrB) is a pro-apoptotic serine protease that contributes to immune-mediated target cell apoptosis.
Closing excerpt
ConclusionIn addition to contributing to ECM degradation and the loss of tissue structural integrity in vivo, increased extracellular GrB activity is also capable of inducing the release of active TGF-β1 from PGs.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (198 words)

ObjectiveGranzyme B (GrB) is a pro-apoptotic serine protease that contributes to immune-mediated target cell apoptosis. However, during inflammation, GrB accumulates in the extracellular space, retains its activity, and is capable of cleaving extracellular matrix (ECM) proteins. Recent studies have implicated a pathogenic extracellular role for GrB in cardiovascular disease, yet the pathophysiological consequences of extracellular GrB activity remain largely unknown. The objective of this study was to identify proteoglycan (PG) substrates of GrB and examine the ability of GrB to release PG-sequestered TGF-β1 into the extracellular milieu.Methods/resultsThree extracellular GrB PG substrates were identified; decorin, biglycan and betaglycan. As all of these PGs sequester active TGF-β1, cytokine release assays were conducted to establish if GrB-mediated PG cleavage induced TGF-β1 release. Our data confirmed that GrB liberated TGF-β1 from all three substrates as well as from endogenous ECM and this process was inhibited by the GrB inhibitor 3,4-dichloroisocoumarin. The released TGF-β1 retained its activity as indicated by the induction of SMAD-3 phosphorylation in human coronary artery smooth muscle cells.ConclusionIn addition to contributing to ECM degradation and the loss of tissue structural integrity in vivo, increased extracellular GrB activity is also capable of inducing the release of active TGF-β1 from PGs.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 22479366 · DOI · PMC3316562

Decorin: A Growth Factor Antagonist for Tumor Growth Inhibition [2]

Review article Järvinen TA, Prince S · · 2015 · cited 94 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Decorin (DCN) is the best characterized member of the extracellular small leucine-rich proteoglycan family present in connective tissues, typically in association with or "decorating" collagen fibrils.
Closing excerpt
In this paper, we review the role of DCN in cancer.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (198 words)

Decorin (DCN) is the best characterized member of the extracellular small leucine-rich proteoglycan family present in connective tissues, typically in association with or "decorating" collagen fibrils. It has substantial interest to clinical medicine owing to its antifibrotic, anti-inflammatory, and anticancer effects. Studies on DCN knockout mice have established that a lack of DCN is permissive for tumor development and it is regarded as a tumor suppressor gene. A reduced expression or a total disappearance of DCN has been reported to take place in various forms of human cancers during tumor progression. Furthermore, when used as a therapeutic molecule, DCN has been shown to inhibit tumor progression and metastases in experimental cancer models. DCN affects the biology of various types of cancer by targeting a number of crucial signaling molecules involved in cell growth, survival, metastasis, and angiogenesis. The active sites for the neutralization of different growth factors all reside in different parts of the DCN molecule. An emerging concept that multiple proteases, especially those produced by inflammatory cells, are capable of cleaving DCN suggests that native DCN could be inactivated in a number of pathological inflammatory conditions. In this paper, we review the role of DCN in cancer.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 26697491 · DOI · PMC4677162

Decorin promotes decidual M1-like macrophage polarization via mitochondrial dysfunction resulting in recurrent pregnancy loss [3]

Research article Wang L, Wang H, Luo J, Xie T, Mor G, Liao A · · 2022 · cited 85 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Rationale: Recurrent pregnancy loss (RPL) is a distressing disorder that seriously affects the physical and psychological health of women.
Closing excerpt
Conclusions: Decidual stromal cell-derived decorin can polarize decidual macrophages toward the M1 phenotype by regulating mitochondrial metabolism, resulting in the occurrence of RPL.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (341 words)

Rationale: Recurrent pregnancy loss (RPL) is a distressing disorder that seriously affects the physical and psychological health of women. RPL is also a sentinel risk marker for future obstetric complications and warrants in-depth investigation. Abnormal polarization and functions of decidual macrophages are associated with RPL; however, the underlying mechanisms remain poorly understood. Methods: Decorin expression, localization, and content in the decidua of women with normal pregnancy (NP) and those with RPL were measured using reverse transcription-quantitative polymerase chain reaction (RT-qPCR), western blotting, immunofluorescence, and enzyme-linked immunosorbent assay. The profiles of decidual macrophage subsets were determined using flow cytometry and immunofluorescence in both groups. The correlation between decorin content and the proportion of decidual macrophage subsets in the decidua of early NP women was determined using Pearson analysis. The effects of decorin on the polarization and functions of macrophages were assessed in an in-vitro model of Raw264.7 cells via flow cytometry, western blotting, and RT-qPCR. Moreover, the mitochondrial metabolism in Raw264.7 cells under decorin administration was measured via flow cytometry, western blotting, and immunofluorescence. Thirty-three pregnant mice were included in the in vivo model and underwent different treatments. The embryo abortion rate, macrophage phenotype in the spleen and uteri, and placental development were evaluated using flow cytometry and hematoxylin-eosin staining. Results: Decorin, derived from decidual stromal cells, was highly expressed in the decidua of women with RPL. A positive correlation between decorin content and the proportion of M1-like macrophages was also observed in the decidua of early NP women. In vitro studies showed that decorin treatment inhibited macrophage polarization to M2-like subsets and boosted the inflammatory response, which was related to enhanced anaerobic glycolysis, increased mitochondrial membrane potential and intracellular reactive oxygen species levels, reduced mitochondrial mass, and activation of the myeloid differentiation primary response 88-nuclear factor-κB signaling pathway. Adoptive transfer of decorin-treated bone marrow-derived macrophages in pregnant C57BL/6 mice increased the embryo absorption, accompanied by impaired fetal vascularization. Conclusions: Decidual stromal cell-derived decorin can polarize decidual macrophages toward the M1 phenotype by regulating mitochondrial metabolism, resulting in the occurrence of RPL.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 36438479 · DOI · PMC9691373

Kisspeptin-10 regulates glycosaminoglycan and decorin content in human cardiac fibroblast cultures [4]

Research article Radwańska P, Olkiewicz M, Piera L, Drobnik J · · 2026

Abstract reading summary — source excerpts
Opening excerpt
BackgroundCardiac fibroblasts play a key role in extracellular matrix (ECM) remodelling through the synthesis of glycosaminoglycans and proteoglycans (PGs), such as decorin; however, the effects of kisspeptin-10 (KiSS-10) on these components in the heart remain unknown.
Closing excerpt
Hence, KiSS-10 may be involved in ECM remodelling in the heart.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (226 words)

BackgroundCardiac fibroblasts play a key role in extracellular matrix (ECM) remodelling through the synthesis of glycosaminoglycans and proteoglycans (PGs), such as decorin; however, the effects of kisspeptin-10 (KiSS-10) on these components in the heart remain unknown. The aim of this study was to determine the influence of KiSS-10 on glycosaminoglycan and decorin content in human cardiac fibroblast cultures and identify its mechanism.MethodsThe effects of KiSS-10 on glycosaminoglycans and decorin were assessed in human cardiac fibroblast cell line, with or without signalling inhibitor. Glycosaminoglycan levels were determined by the Farndale method, decorin secretion by enzyme-linked immunosorbent assay (ELISA), and decorin expression by quantitative polymerase chain reaction (qPCR).ResultsKiSS-10 treatment caused a dose-dependent increase in glycosaminoglycan content in both cells and medium. This stimulatory effect was abolished by blocking G-protein-coupled receptor 54 (GPR54) with peptide 234 or focal adhesion kinase (FAK) with FAK inhibitor 14 (FAKi). Combining KiSS-10 with phospholipase C inhibitor (D609) did not alter the glycosaminoglycan level compared to KiSS-10 alone. KiSS-10 increased decorin secretion but not expression. Combining peptide 234 with KiSS-10 did not alter media decorin level compared to KiSS-10 alone.ConclusionsKiSS-10 significantly elevated glycosaminoglycan and decorin accumulation in human cardiac fibroblast cultures. This regulatory effect on glycosaminoglycan level appears to be dependent on GPR54 activation and FAK signalling, but not on phospholipase C function. Hence, KiSS-10 may be involved in ECM remodelling in the heart.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42159865 · DOI · PMC13437659

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Decorin: a guardian from the matrix [5]
    Neill T, Schaefer L, Iozzo RV · Am J Pathol · 2012 · cited 262 times (Europe PMC)
  • Research article Decorin interacting network: A comprehensive analysis of decorin-binding partners and their versatile functions [6]
    Gubbiotti MA, Vallet SD, Ricard-Blum S, Iozzo RV · Matrix Biol · 2016 · cited 199 times (Europe PMC)
  • Research article Pivotal role for decorin in angiogenesis [7]
    Järveläinen H, Sainio A, Wight TN · Matrix Biol · 2015 · cited 149 times (Europe PMC)
  • Research article Decorin-TGFβ axis in hepatic fibrosis and cirrhosis [8]
    Baghy K, Iozzo RV, Kovalszky I · J Histochem Cytochem · 2012 · cited 149 times (Europe PMC)
  • Research article Proteoglycan neofunctions: regulation of inflammation and autophagy in cancer biology [9]
    Schaefer L, Tredup C, Gubbiotti MA, Iozzo RV · FEBS J · 2017 · cited 136 times (Europe PMC)
  • Research article Decorin as a multivalent therapeutic agent against cancer [10]
    Neill T, Schaefer L, Iozzo RV · Adv Drug Deliv Rev · 2016 · cited 128 times (Europe PMC)

References

  1. Boivin WA, Shackleford M, Vanden Hoek A, Zhao H, Hackett TL, Knight DA, et al.. Granzyme B cleaves decorin, biglycan and soluble betaglycan, releasing active transforming growth factor-β1. . 2012. PMID 22479366 · DOI · PMC3316562
  2. Järvinen TA, Prince S. Decorin: A Growth Factor Antagonist for Tumor Growth Inhibition. . 2015. PMID 26697491 · DOI · PMC4677162
  3. Wang L, Wang H, Luo J, Xie T, Mor G, Liao A. Decorin promotes decidual M1-like macrophage polarization via mitochondrial dysfunction resulting in recurrent pregnancy loss. . 2022. PMID 36438479 · DOI · PMC9691373
  4. Radwańska P, Olkiewicz M, Piera L, Drobnik J. Kisspeptin-10 regulates glycosaminoglycan and decorin content in human cardiac fibroblast cultures. . 2026. PMID 42159865 · DOI · PMC13437659
  5. Neill T, Schaefer L, Iozzo RV. Decorin: a guardian from the matrix. Am J Pathol. 2012. PMID 22735579 · DOI · PMC3409438
  6. Gubbiotti MA, Vallet SD, Ricard-Blum S, Iozzo RV. Decorin interacting network: A comprehensive analysis of decorin-binding partners and their versatile functions. Matrix Biol. 2016. PMID 27693454 · DOI · PMC6938589
  7. Järveläinen H, Sainio A, Wight TN. Pivotal role for decorin in angiogenesis. Matrix Biol. 2015. PMID 25661523 · DOI · PMC4560244
  8. Baghy K, Iozzo RV, Kovalszky I. Decorin-TGFβ axis in hepatic fibrosis and cirrhosis. J Histochem Cytochem. 2012. PMID 22260996 · DOI · PMC3351239
  9. Schaefer L, Tredup C, Gubbiotti MA, Iozzo RV. Proteoglycan neofunctions: regulation of inflammation and autophagy in cancer biology. FEBS J. 2017. PMID 27860287 · DOI · PMC5226885
  10. Neill T, Schaefer L, Iozzo RV. Decorin as a multivalent therapeutic agent against cancer. Adv Drug Deliv Rev. 2016. PMID 26522384 · DOI · PMC4753134

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-31.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • ProteoglycansDrugs and Chemicals
  • Heparan Sulfate ProteoglycansDrugs and Chemicals
  • OsteopontinDrugs and Chemicals
  • LamininDrugs and Chemicals
  • VitronectinDrugs and Chemicals
  • Syndecan-1Drugs and Chemicals

All 546 articles in Drugs and Chemicals →

At a glance

1,846
PubMed records on this heading
16%
published since 2020
121
review articles
13
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • ProteoglycansDrugs and Chemicals
  • Heparan Sulfate ProteoglycansDrugs and Chemicals
  • OsteopontinDrugs and Chemicals
  • LamininDrugs and Chemicals
  • VitronectinDrugs and Chemicals

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support